Synopses & Reviews
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance.
Synopsis
This book examines antibody-mediated anti-cancer therapy, covering the use of mAbs against various cancers, developments in
About the Author
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
Table of Contents
Part I. Immunotherapy with monoclonal antibodies (mAbs) against various cancers 1.Introduction and generation of chimeric and humanized mAbs 2. mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment 3. Antibodies directed against different major cancers: Effects when used alone or in combination with drugs 4. Mechanisms of antibodies-mediated responses, in vitro and in vivo Part II. Development of resistance to mAbs 5. Molecular Pathways 6. Molecular Signatures 7. Identification of resistance targets for intervention Part III. Agents that can sensitize resistant tumor cells to mAbs 8. Various chemicals that can sensitize resitant tumor cells 9. Other mAbs 10. Proteasome inhibitors Part IV. Novel mAbs to overcome resistance 11. Divalent mAbs 12. Antibodies coupled to chemical inhibitors 13. Antibodies coupled to cytokines 14. Nanoparticles with mAbs